Implantica schedules Q3 briefing on implantable technology business

Implantica has scheduled an investor presentation for its third-quarter 2026 results on 19 November at 15:00 CET, according to a company announcement distributed through PR Newswire.

The company said its interim report would be published at 08:00 CET that day, seven hours before the briefing. The announcement does not contain quarterly financial results or provide revenue, earnings or sales guidance.

Chief executive Peter Forsell, chief financial officer Andreas Öhrnberg and chief corporate affairs officer Nicole Pehrsson are listed as speakers. The presentation will be delivered in English through a webcast and teleconference.

Investors can access the webcast through the Inderes event link supplied in the announcement. Teleconference participants must register separately to receive a telephone number and conference ID.

Implantica describes its business as developing implantable medical technologies intended to improve patient outcomes and quality of life. Its lead product, RefluxStop, is an implant for treating gastroesophageal reflux disease.

The company says RefluxStop is approved by the US Food and Drug Administration and carries a CE mark. It also claims strong long-term clinical outcomes, but the supplied announcement does not include clinical data or regulatory documentation to substantiate those statements.

Beyond RefluxStop, Implantica says its product pipeline partly incorporates an eHealth platform designed for communication with, and remote monitoring and control of, implants inside the body. A second platform is designed to power implantable devices wirelessly through intact skin.

The company describes these devices as investigational and says they are intended to allow remote treatment changes. The announcement does not establish when they might become commercially available.

Implantica is listed on Stockholm’s Nasdaq First North Premier Growth Market under the ticker IMP A SDB. Its Certified Adviser is FNCA Sweden AB.